share_log

F-1/A: Registration statement for securities of certain Canadian issuers (Amendment)

F-1/A: Registration statement for securities of certain Canadian issuers (Amendment)

F-1/A：证券登记表(修正)
美股sec公告 ·  05/20 16:24
Moomoo AI 已提取核心信息
NeuroSense Therapeutics Ltd. (NeuroSense), a clinical-stage biotechnology company, has filed an amendment to its Form F-1 registration statement with the U.S. Securities and Exchange Commission (SEC) on May 20, 2024. The amendment pertains to the registration of up to 3,050,964 ordinary shares and 2,980,000 ordinary warrants for sale to the public. The ordinary warrants have an exercise price of $1.50 per share and are exercisable immediately upon issuance until April 15, 2029. Additionally, 70,964 ordinary shares were issued to the placement agent as partial consideration for their services in connection with the April 2024 offering. The company's ordinary shares and warrants are listed on The Nasdaq Capital Market under the symbols 'NRSN' and 'NRSNW,' respectively. The proceeds from the exercise of the warrants, if any, are intended for general corporate purposes and working capital. The registration statement also includes details on the company's ability to indemnify its officers and directors, and the legal and financial advisors involved in the filing.
NeuroSense Therapeutics Ltd. (NeuroSense), a clinical-stage biotechnology company, has filed an amendment to its Form F-1 registration statement with the U.S. Securities and Exchange Commission (SEC) on May 20, 2024. The amendment pertains to the registration of up to 3,050,964 ordinary shares and 2,980,000 ordinary warrants for sale to the public. The ordinary warrants have an exercise price of $1.50 per share and are exercisable immediately upon issuance until April 15, 2029. Additionally, 70,964 ordinary shares were issued to the placement agent as partial consideration for their services in connection with the April 2024 offering. The company's ordinary shares and warrants are listed on The Nasdaq Capital Market under the symbols 'NRSN' and 'NRSNW,' respectively. The proceeds from the exercise of the warrants, if any, are intended for general corporate purposes and working capital. The registration statement also includes details on the company's ability to indemnify its officers and directors, and the legal and financial advisors involved in the filing.
处于临床阶段的生物技术公司NeuroSense Therapeutics Ltd.（NeuroSense）已于2024年5月20日向美国证券交易委员会（SEC）提交了其F-1表格注册声明的修正案。该修正案涉及最多3,050,964股普通股和298万份普通认股权证的注册，以向公众出售。普通认股权证的行使价为每股1.50美元，可在发行后立即行使，直至2029年4月15日。此外，向配售代理人发行了70,964股普通股，作为其与2024年4月发行相关的服务的部分对价。该公司的普通股和认股权证分别在纳斯达克资本市场上市，代码分别为 “NRSN” 和 “NRSNW”。行使认股权证的收益（如果有）将用于一般公司用途和营运资金。注册声明还包括有关公司向其高管和董事以及参与申报的法律和财务顾问进行赔偿的能力的详细信息。
处于临床阶段的生物技术公司NeuroSense Therapeutics Ltd.（NeuroSense）已于2024年5月20日向美国证券交易委员会（SEC）提交了其F-1表格注册声明的修正案。该修正案涉及最多3,050,964股普通股和298万份普通认股权证的注册，以向公众出售。普通认股权证的行使价为每股1.50美元，可在发行后立即行使，直至2029年4月15日。此外，向配售代理人发行了70,964股普通股，作为其与2024年4月发行相关的服务的部分对价。该公司的普通股和认股权证分别在纳斯达克资本市场上市，代码分别为 “NRSN” 和 “NRSNW”。行使认股权证的收益（如果有）将用于一般公司用途和营运资金。注册声明还包括有关公司向其高管和董事以及参与申报的法律和财务顾问进行赔偿的能力的详细信息。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息